The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells

Mano Horinaka, Tatsushi Yoshida, Takumi Shiraishi, Susumu Nakata, Miki Wakada, Ryoko Nakanishi, Hoyoku Nishino, Toshiyuki Sakai

Research output: Contribution to journalArticle

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the most promising candidates for cancer therapeutics. However, some tumor cells are resistant to TRAIL-induced apoptosis. Our previous studies have shown that luteolin, a naturally occurring flavonoid, induces the up-regulation of death receptor 5 (DR5), which is a receptor for TRAIL. Here, we show for the first time that luteolin synergistically acts with exogenous soluble recombinant human TRAIL to induce apoptosis in HeLa cells, but not in normal human peripheral blood mononuclear cells. The combined use of luteolin and TRAIL induced Bid cleavage and the activation of caspase-8. Also, human recombinant DR5/Fc chimera protein, caspase inhibitors, and DR5 siRNA efficiently reduced apoptosis induced by co-treatment with luteolin and TRAIL. These results raise the possibility that this combined treatment with luteolin and TRAIL might be promising as a new therapy against cancer.

Original languageEnglish (US)
Pages (from-to)833-838
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume333
Issue number3
DOIs
StatePublished - Aug 5 2005
Externally publishedYes

Fingerprint

Luteolin
TNF-Related Apoptosis-Inducing Ligand Receptors
HeLa Cells
Uterine Cervical Neoplasms
Apoptosis
Neoplasms
Caspase Inhibitors
Caspase 8
Flavonoids
Small Interfering RNA
Tumors
Blood Cells
Blood
Up-Regulation
Tumor Necrosis Factor-alpha
Chemical activation
Cells
Ligands
Therapeutics
Proteins

Keywords

  • Apoptosis
  • Cancer
  • Caspase
  • Combination
  • DR5
  • Flavonoid
  • Luteolin
  • TRAIL

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Horinaka, M., Yoshida, T., Shiraishi, T., Nakata, S., Wakada, M., Nakanishi, R., ... Sakai, T. (2005). The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochemical and Biophysical Research Communications, 333(3), 833-838. https://doi.org/10.1016/j.bbrc.2005.05.179

The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. / Horinaka, Mano; Yoshida, Tatsushi; Shiraishi, Takumi; Nakata, Susumu; Wakada, Miki; Nakanishi, Ryoko; Nishino, Hoyoku; Sakai, Toshiyuki.

In: Biochemical and Biophysical Research Communications, Vol. 333, No. 3, 05.08.2005, p. 833-838.

Research output: Contribution to journalArticle

Horinaka, M, Yoshida, T, Shiraishi, T, Nakata, S, Wakada, M, Nakanishi, R, Nishino, H & Sakai, T 2005, 'The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells', Biochemical and Biophysical Research Communications, vol. 333, no. 3, pp. 833-838. https://doi.org/10.1016/j.bbrc.2005.05.179
Horinaka, Mano ; Yoshida, Tatsushi ; Shiraishi, Takumi ; Nakata, Susumu ; Wakada, Miki ; Nakanishi, Ryoko ; Nishino, Hoyoku ; Sakai, Toshiyuki. / The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. In: Biochemical and Biophysical Research Communications. 2005 ; Vol. 333, No. 3. pp. 833-838.
@article{0ddff5daa104414aab6d41754641de6a,
title = "The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells",
abstract = "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the most promising candidates for cancer therapeutics. However, some tumor cells are resistant to TRAIL-induced apoptosis. Our previous studies have shown that luteolin, a naturally occurring flavonoid, induces the up-regulation of death receptor 5 (DR5), which is a receptor for TRAIL. Here, we show for the first time that luteolin synergistically acts with exogenous soluble recombinant human TRAIL to induce apoptosis in HeLa cells, but not in normal human peripheral blood mononuclear cells. The combined use of luteolin and TRAIL induced Bid cleavage and the activation of caspase-8. Also, human recombinant DR5/Fc chimera protein, caspase inhibitors, and DR5 siRNA efficiently reduced apoptosis induced by co-treatment with luteolin and TRAIL. These results raise the possibility that this combined treatment with luteolin and TRAIL might be promising as a new therapy against cancer.",
keywords = "Apoptosis, Cancer, Caspase, Combination, DR5, Flavonoid, Luteolin, TRAIL",
author = "Mano Horinaka and Tatsushi Yoshida and Takumi Shiraishi and Susumu Nakata and Miki Wakada and Ryoko Nakanishi and Hoyoku Nishino and Toshiyuki Sakai",
year = "2005",
month = "8",
day = "5",
doi = "10.1016/j.bbrc.2005.05.179",
language = "English (US)",
volume = "333",
pages = "833--838",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells

AU - Horinaka, Mano

AU - Yoshida, Tatsushi

AU - Shiraishi, Takumi

AU - Nakata, Susumu

AU - Wakada, Miki

AU - Nakanishi, Ryoko

AU - Nishino, Hoyoku

AU - Sakai, Toshiyuki

PY - 2005/8/5

Y1 - 2005/8/5

N2 - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the most promising candidates for cancer therapeutics. However, some tumor cells are resistant to TRAIL-induced apoptosis. Our previous studies have shown that luteolin, a naturally occurring flavonoid, induces the up-regulation of death receptor 5 (DR5), which is a receptor for TRAIL. Here, we show for the first time that luteolin synergistically acts with exogenous soluble recombinant human TRAIL to induce apoptosis in HeLa cells, but not in normal human peripheral blood mononuclear cells. The combined use of luteolin and TRAIL induced Bid cleavage and the activation of caspase-8. Also, human recombinant DR5/Fc chimera protein, caspase inhibitors, and DR5 siRNA efficiently reduced apoptosis induced by co-treatment with luteolin and TRAIL. These results raise the possibility that this combined treatment with luteolin and TRAIL might be promising as a new therapy against cancer.

AB - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the most promising candidates for cancer therapeutics. However, some tumor cells are resistant to TRAIL-induced apoptosis. Our previous studies have shown that luteolin, a naturally occurring flavonoid, induces the up-regulation of death receptor 5 (DR5), which is a receptor for TRAIL. Here, we show for the first time that luteolin synergistically acts with exogenous soluble recombinant human TRAIL to induce apoptosis in HeLa cells, but not in normal human peripheral blood mononuclear cells. The combined use of luteolin and TRAIL induced Bid cleavage and the activation of caspase-8. Also, human recombinant DR5/Fc chimera protein, caspase inhibitors, and DR5 siRNA efficiently reduced apoptosis induced by co-treatment with luteolin and TRAIL. These results raise the possibility that this combined treatment with luteolin and TRAIL might be promising as a new therapy against cancer.

KW - Apoptosis

KW - Cancer

KW - Caspase

KW - Combination

KW - DR5

KW - Flavonoid

KW - Luteolin

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=20744456317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20744456317&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2005.05.179

DO - 10.1016/j.bbrc.2005.05.179

M3 - Article

VL - 333

SP - 833

EP - 838

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -